Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“Big Pharma just made one of its boldest AI bets yet.
Eli Lilly and Company has struck a $2.75B deal to bring AI-designed drugs to the global market-partnering with Insilico Medicine. ‘
What’s happening:
- AI is being used to design novel drug candidates from scratch •
- Lilly gets global rights to develop + commercialize these therapies
- $115M upfront, with billions in milestone + royalty potential
Why this matters:
This isn’t incremental innovation-this is a paradigm shift in drug development.
Traditional pipeline:
- 10–15 years
- Billions in cost
- High failure rates
AI-driven pipeline:
- Rapid target discovery
- Smarter molecule design
- Potentially faster + cheaper translation
We’re watching the industrialization of drug discovery.”
Other articles featuring Yan Leyfman.